Mga Batayang Estadistika
| CIK | 1502152 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to GlobeStar Therapeutics Corporation
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 333-170315 GlobeStar Therapeutics Corporation (Exact name of registrant as s |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2024 GlobeStar Therapeutics Corporation (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation) (C |
|
| October 11, 2024 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 GlobeStar Therape |
|
| August 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 April 30, 2025 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 000-55072 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10-D [] Form N-CEN [] Form N-CSR For Period Ended: June 30, 2024 [] |
|
| June 28, 2024 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 GlobeStar Therap |
|
| May 17, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 April 30, 2025 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 000-55072 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10-D [] Form N-CEN [] Form N-CSR For Period Ended: March 31, 2024 [ |
|
| March 12, 2024 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 GlobeStar The |
|
| February 15, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 April 30, 2025 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 000-55072 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10-D [] Form N-CEN [] Form N-CSR For Period Ended: December 31, 202 |
|
| January 19, 2024 |
Subsidiaries of the Registrant Exhibit 21 SUBSIDIARIES OF THE REGISTRANT SomaCeuticals, Inc. (a Texas corporation) First Titan Energy, LLC, (a Nevada limited liability company) First Titan Technical, LLC, (a Nevada limited liability company) |
|
| January 19, 2024 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 GlobeStar Therapeuti |
|
| January 2, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 April 30, 2025 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 000-55072 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [X] Form 10-K [] Form 20-F [] Form 11-K [] Form 10-Q [] Form 10-D [] Form N-CEN [] Form N-CSR For Period Ended: September 30, 20 |
|
| November 13, 2023 |
Exhibit 99.2 Collaboration Agreement This Collaboration Agreement (“Agreement”) dated September 26, 2023, is entered into by and between: (1) GlobeStar Therapeutics Corporation, a Wyoming corporation (“GlobeStar”), 719 Jadwin Ave, Richland, Washington 99352, email: [email protected], and its wholly-owned subsidiary, SomaCeuticals, Inc., a Texas corporation, (“Soma”), 2500 Wilcrest Drive, Suite 300 |
|
| November 13, 2023 |
Exhibit 99.1 Consulting Agreement This Consulting Agreement (“Agreement”) dated November 2, 2023, is entered into by and between GlobeStar Therapeutics Corporation, a Wyoming corporation (“GlobeStar”) and Advanced Innovative Partners, Inc., a Wyoming corporation (“AIP”). Each of GlobeStar and AIP is sometimes referred to herein as a “Party” and collectively as the “Parties.” Now, Therefore, the Pa |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 26, 2023 GlobeStar Therapeutics Corporation (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation |
|
| August 17, 2023 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 GlobeStar Therape |
|
| August 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 April 30, 2025 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 000-55072 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10-D [] Form N-CEN [] Form N-CSR For Period Ended: June 30, 2023 [] |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 27, 2023 GlobeStar Therapeutics Corporation (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation) (Co |
|
| June 27, 2023 |
Letter from M&K CPAS, PLLC dated June 27, 2023 Exhibit 16.1 June 27, 2023 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Dear Sir/Madam: We have read the statements included under Item 4.01 in the Form 8-K dated June 27, 2023 of GlobeStar Therapeutics Corporation (the “Company”) to be filed with the Securities and Exchange Commission regarding the change of auditors. We agree with such |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 21, 2023 GlobeStar Therapeutics Corporation (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation) (Co |
|
| June 22, 2023 |
Exhibit 99.1 GLOBESTAR THERAPEUTICS ENTERS INTO MOU WITH ADVANCED INNOVATIVE PARTNERS TO DEVELOP CLINICAL STUDIES FOR MULTIPLE SCLEROSIS TREATMENT RICHLAND, WA & PALM BEACH, FL (June 13, 2023). GlobeStar Therapeutics Corporation (OTC PINK:GSTC) (GSTC), a clinical-stage pharmaceutical company focused on advancing new therapies for Multiple Sclerosis (MS) and other neurological diseases, and Advance |
|
| May 31, 2023 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) Table of Contents UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-17031 |
|
| May 15, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 April 30, 2025 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 000-55072 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10-D [] Form N-CEN [] Form N-CSR For Period Ended: March 31, 2023 [ |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 4, 2023 GlobeStar Therapeutics Corporation (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation) (Co |
|
| February 13, 2023 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) Table of Contents UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-17 |
|
| January 9, 2023 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 GlobeStar Therapeuti |
|
| January 9, 2023 |
Subsidiaries of the Registrant EX-21 2 ex21.htm SUBSIDIARIES OF THE REGISTRANT Exhibit 21 SUBSIDIARIES OF THE REGISTRANT SomaCeuticals, Inc. (a Texas corporation) First Titan Energy, LLC, (a Nevada limited liability company) First Titan Technical, LLC, (a Nevada limited liability company) |
|
| December 29, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NT 10-K 1 form12b-25.htm FORM 12B-25 (NT 10-K) NOTIFICATION OF LATE FILING FOR 09-30-2022 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 April 30, 2025 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 000-55072 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [X] Form 10-K [] Form 20-F [] Form 11- |
|
| August 23, 2022 |
Table of Contents UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File |
|
| August 22, 2022 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) Table of Contents UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 |
|
| August 15, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 April 30, 2025 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 000-55072 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10-D [] Form N-CEN [] Form N-CSR For Period Ended: June 30, 2022 [] |
|
| June 1, 2022 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 GlobeStar Therap |
|
| May 16, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NT 10-Q 1 form12b-25.htm FORM 12B-25 (NT 10-Q) NOTIFICATION OF LATE FILING FOR 03-31-2022 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 April 30, 2025 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 000-55072 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [] Form 10-K [] Form 20-F [] Form 11-K |
|
| April 11, 2022 |
Regulation FD Disclosure, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 6, 2022 GlobeStar Therapeutics Corporation (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation) (Co |
|
| February 14, 2022 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 GlobeStar The |
|
| January 5, 2022 |
Subsidiaries of the Registrant Exhibit 21 SUBSIDIARIES OF THE REGISTRANT SomaCeuticals, Inc. (a Texas corporation) First Titan Energy, LLC, (a Nevada limited liability company) First Titan Technical, LLC, (a Nevada limited liability company) |
|
| January 5, 2022 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 GlobeStar Therapeuti |
|
| December 30, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 February 28, 2022 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 000-55072 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [X] Form 10-K [] Form 20-F [] Form 11-K [] Form 10-Q [] Form 10-D [] Form N-CEN [] Form N-CSR For Period Ended: September 30, |
|
| October 12, 2021 |
GlobeStar Therapeutics Corporation Has Been Upgraded to the QB Tier on OTC Markets. Exhibit 99.1 GlobeStar Therapeutics Corporation Has Been Upgraded to the QB Tier on OTC Markets. Company will move from the Pink tier to QB tier effective immediately while retaining the same ticker symbol. Richland, Washington. October 11, 2021 GlobeStar Therapeutics Corporation (OTCQB: GSTC) (www.globestarthera.com) headquartered in Richland, Washington, is a fast-growing company focused on prov |
|
| October 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 11, 2021 GlobeStar Therapeutics Corporation (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation) |
|
| October 4, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 4, 2021 GlobeStar Therapeutics Corporation (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation) ( |
|
| October 4, 2021 |
GlobeStar Therapeutics Corporation Additional Progress Toward U.S.-Based Clinical Trial. Exhibit 99.1 GlobeStar Therapeutics Corporation Additional Progress Toward U.S.-Based Clinical Trial. Company has made progress with a major medical center in the Northeast and identified a path forward for this pharmaceutical. October 4, 2021 RICHLAND, WASH. GlobeStar Therapeutics Corporation (OTCBB: GSTC ) (www.globestarthera.com) headquartered in Richland, Washington, is a fast-growing company |
|
| October 4, 2021 |
Exhibit 99.2 |
|
| September 20, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 20, 2021 GlobeStar Therapeutics Corporation (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation |
|
| September 20, 2021 |
Multiple Sclerosis Drug Development Information September 2021 EX-99 2 ex99-1.htm MULTIPLE SCLEROSIS DRUG DEVELOPMENT INFORMATION SEPT. 2021 Exhibit 99.1 Multiple Sclerosis Drug Development Information September 2021 |
|
| August 23, 2021 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 GlobeStar Therape |
|
| August 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 February 28, 2022 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 000-55072 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10-D [] Form N-CEN [] Form N-CSR For Period Ended: June 30, 2021 |
|
| May 21, 2021 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma Inc. ( |
|
| May 17, 2021 |
NT 10-Q 1 form12b-25.htm FORM 12B-25 (NT 10-Q) FOR 03-31-2021 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 February 28, 2022 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 000-55072 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10 |
|
| May 6, 2021 |
Exhibit 99.3 AngioSoma, Inc. is Pleased to Welcome Steven F. Penderghast to its Board of Directors Penderghast's Experience Medical Sciences Will Play a Key Role in the Growth of AngioSoma RICHLAND, WA / ACCESSWIRE / April 21, 2021 / AngioSoma, Inc. (OTC PINK:SOAN) has added Steven F. Penderghast to its Board of Directors. Penderghast has experience working in medical sciences, as well as his lead |
|
| May 6, 2021 |
Exhibit 99.1 AngioSoma, Inc. Adds Brooke Greenwald As Chief Marketing Officer Greenwald?s experience in public relations and marketing will play a key role in the growth of AngioSoma. RICHLAND, WASH. AngioSoma, Inc. (OTCBB: SOAN) has hired Brooke Greenwald as its Chief Marketing Officer. Ms. Greenwald brings decades of experience spearheading the marketing and communications efforts of pharmaceuti |
|
| May 6, 2021 |
Exhibit 99.2 AngioSoma, Inc. Adds David Croom As Executive Vice President Croom?s experience in finance, sales, and operations will play a key role in the growth of AngioSoma. RICHLAND, WASH. AngioSoma, Inc. (OTCBB: SOAN) has hired David Croom as an Executive Vice President. Mr. Croom brings decades of experience in finance, sales, and operations to the AngioSoma team. In this role, he will have b |
|
| May 6, 2021 |
Exhibit 99.4 AngioSoma, Inc. Is Pleased To Welcome Dr. Leonard Wisneski, MD, FACP As The Medical Advisory Board Chairman Dr. Wisneski?s medical and teaching experience will play a key role in the growth of AngioSoma. RICHLAND, WA / ACCESSWIRE / May 4, 2021 / AngioSoma, Inc. (OTC PINK:SOAN) has added Dr. Leonard Wisneski, MD, FACP as the Chair of the Medical Advisory Board. Dr. Wisneski?s experienc |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2021 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2021 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 16, 2021 |
Exhibit 99.1 AngioSoma, Inc. Is Pleased to Welcome William Farley to Its Board of Directors Farley?s experience in discovery and development will play a key role in the growth of AngioSoma. RICHLAND, WA / ACCESSWIRE / April 15, 2021 / AngioSoma, Inc. (OTC PINK:SOAN) has added William ?Bill? Farley to its Board of Directors. Farley?s experience in discovery and development, as well as his leadershi |
|
| April 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 14, 2021 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 5, 2021 |
8-K 1 form8-k.htm FORM 8-K CURRENT REPORT FOR 03-03-2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 3, 2021 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or ot |
|
| February 25, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K CURRENT REPORT FOR 02-04-2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 4, 2021 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 25, 2021 |
Exhibit 99.1 Angiosoma and its Subsidiary Somaceuticals Announce Amended and Restated Execution of Global License for Multiple Sclerosis Patent Houston, February 11, 2021 - AngioSoma Inc. (OTC: SOAN) (?AngioSoma? or the ?Company?), through its wholly-owned subsidiary, SomaCeuticals, Inc., is pleased to announce that the Exclusive Global Multiple Sclerosis License Agreement dated August 23, 2020 ha |
|
| January 28, 2021 |
Quarterly Report - FORM 10-Q QUARTERLY REPORT FOR 12-31-2020 UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma Inc |
|
| December 22, 2020 |
Regulation FD Disclosure - FORM 8-K CURRENT REPORT FOR 12-22-2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 22, 2020 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 9, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K CURRENT REPORT FOR 12-07-2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 7, 2020 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 9, 2020 |
SomaCeuticals Moving Forward With Treatment of Multiple Sclerosis Exhibit 99.1 SomaCeuticals Moving Forward With Treatment of Multiple Sclerosis Houston, December 8, 2020 - AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the Company’s subsidiary, SomaCeuticals, Inc., has defined its mission to bring its enhanced treatment for Multiple Sclerosis to patients worldwide. After an intensive search, the Company has identified a we |
|
| December 3, 2020 |
Subsidiaries of the Registrant (4) Exhibit 21 SUBSIDIARIES OF THE REGISTRANT SomaCeuticals, Inc. (a Texas corporation) First Titan Energy, LLC, (a Nevada limited liability company) First Titan Technical, LLC, (a Nevada limited liability company) |
|
| December 3, 2020 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma, Inc. (Exa |
|
| August 24, 2020 |
SomaCeuticals Acquires License for Treatment of Multiple Sclerosis Exhibit 99.1 SomaCeuticals Acquires License for Treatment of Multiple Sclerosis Houston, August 24, 2020 - AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the company’s subsidiary, SomaCeuticals, Inc., has executed a licensing agreement with 7 to Stand, Inc. (a Delaware corporation) for the exclusive global rights to U.S. patent 10,610,592 issued to Fabrizio d |
|
| August 24, 2020 |
- FORM 8-K CURRENT REPORT FOR 08-12-2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2020 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 23, 2020 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Wyoming 333-170315 27-3480481 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 14, 2020 |
Quarterly Report - FORM 10-Q QUARTERLY REPORT FOR 06-30-2020 UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma Inc. (E |
|
| May 5, 2020 |
Quarterly Report - FORM 10-Q QUARTERLY REPORT FOR 03-31-2020 UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma Inc. ( |
|
| March 9, 2020 |
EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing, along with all other such undersigned, on behalf of the Reporting Persons (as defined in the joint filing), of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value |
|
| March 9, 2020 |
SOAN / AngioSoma, Inc. / Atwood Brent - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 1) Under the Securities Exchange Act of 1934 ANGIOSOMA INC. (Name of Issuer) Common Stock (Title of Class of Securities) 03476L102 (CUSIP Number) Brent Atwood 5000 Riverside Drive Ste 100E Bldg 6 Irving, Texas 75039 Telephone: (907) 738-8458 With a copy to: John Cooley 5000 Riverside Drive Ste 100 |
|
| March 9, 2020 |
Exhibit 99.2 Trading Data Name of Seller Sale Date No. of Shares Sold Price Per Share(1) Nature of Purchase(2) Equine Charter Private Equity Fund VII, LLC 2020-02-25 2,750,000 0.001 Broker’s Transaction EQuine Holdings Charter Private Equity Fund XIII 13 2020-02-25 7,447,200 0.001 Broker’s Transaction Equine Charter Private Equity Fund XX 2020-02-25 6,927,500 0.001 Broker’s Transaction Equine Char |
|
| February 14, 2020 |
SOAN / AngioSoma, Inc. 10-Q - Quarterly Report - FORM 10-Q QUARTERLY REPORT FOR 12-31-2019 UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma Inc |
|
| December 31, 2019 |
SOAN / AngioSoma, Inc. NT 10-K - - FORM NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition P |
|
| December 31, 2019 |
Subsidiaries of the Registrant (4) Exhibit 21 SUBSIDIARIES OF THE REGISTRANT SomaCeuticals, Inc. (a Texas corporation) First Titan Energy, LLC, (a Nevada limited liability company) First Titan Technical, LLC, (a Nevada limited liability company) |
|
| December 31, 2019 |
SOAN / AngioSoma, Inc. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma, Inc. (Exa |
|
| November 1, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (D) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 28, 2019 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 333-170315 27-3480481 (State of Incorporation) (Commission File Number) (IRS Employer Identification N |
|
| October 28, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (D) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 25, 2019 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 333-170315 27-3480481 (State of Incorporation) (Commission File Number) (IRS Employer Identification N |
|
| October 23, 2019 |
Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (D) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 16, 2019 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 333-170315 27-3480481 (State of Incorporation) (Commission File Number) (IRS Employer Identification N |
|
| October 23, 2019 |
AngioSoma, Inc. Announces Settlement of Litigation EXHIBIT 99.1 AngioSoma, Inc. Announces Settlement of Litigation Houston, Texas October 22, 2019 – AngioSoma, Inc. (OTC: SOAN) is pleased to announce the Company has executed a Settlement Agreement of the litigation with David Summers. The Agreement covers all related claims and controversies between the Company, our wholly owned subsidiary, and Mr. Summers. In addition, the Agreement includes a mu |
|
| September 24, 2019 |
SOAN / AngioSoma, Inc. DEF 14A - - SCHEDULE 14A DEFINITIVE PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Under Rule 14(a)(12) AngioSoma, Inc. |
|
| September 10, 2019 |
SOAN / AngioSoma, Inc. PRE 14A - - SCHEDULE 14A PRELIMINARY PROXY STATEMENT PRE 14A 1 schedule14a.htm SCHEDULE 14A PRELIMINARY PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Prox |
|
| August 21, 2019 |
SOAN / AngioSoma, Inc. / Atwood Brent Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 ANGIOSOMA INC. (Name of Issuer) Common Stock (Title of Class of Securities) 03476L102 (CUSIP Number) Brent Atwood 5000 Riverside Drive Ste 100E Bldg 6 Irving, Texas 75039 Telephone: (907) 738-8458 With a copy to: John Cooley 5000 Riverside Drive Ste 100E Bldg 6 Irving, Tex |
|
| August 21, 2019 |
EXHIBIT 99.2 Trading Data Name of Purchaser Purchase Date No. of Shares Purchased Price per Share Nature of Purchase eQuine Charter Private Equity Fund VII, LLC 8/13/2019 1,750,000 $0.02 Broker’s Transaction eQuine Charter Private Equity Fund VII, LLC 8/14/2019 500,000 $0.02 Broker’s Transaction Equine Charter Private Equity Fund XII 8/12/2019 1,104,995 $0.01 Broker’s Transaction Equine Charter Pr |
|
| August 21, 2019 |
EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing, along with all other such undersigned, on behalf of the Reporting Persons (as defined in the joint filing), of a statement on Schedule 13D (including amendments thereto) with respect to the common stoc |
|
| August 20, 2019 |
Angiosoma, Inc. Confirms Status Of Voting Control EX-99 2 ex99-1.htm PRESS RELEASE EXHIBIT 99.1 Angiosoma, Inc. Confirms Status Of Voting Control Houston, Texas August 19, 2019 – AngioSoma, Inc. (OTC: SOAN) announced today the Company has filed an amendment to its Form 10-K for the fiscal year ended September 30, 2018 as well as an amendment to the previously filed Form 13D of the President & CEO, Alex Blankenship, to confirm that, effective May |
|
| August 20, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 form8-k.htm FORM 8-K CURRENT REPORT FOR 08-16-2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 16, 2019 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 333-170315 27-3480481 (State or o |
|
| August 20, 2019 |
Certificate of Correction filed with the Secretary of State of Nevada February 14, 2018. Exhibit 3.2 State Seal BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate of Correction (PURSUANT TO NRS CHAPTERS 78, 78A, 80, 8l, 82, 84, 86, 87, 87A, 88, 88A, 89 AND 92A) Filed in the office of /s/ Barbara K. Cegavske Barbara K. Cegavske Secretary of State State of Nevada Document Number 20180071268-05 F |
|
| August 20, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Rule 13d-101 Amendment Number 1 Under the Securities Exchange Act of 1934 AngioSoma, Inc. (Name of Issuer) Series E Preferred Stock, par value $.001 per share (Title of Class of Securities) None (CUSIP Number) Alex K. Blankenship 2500 Wilcrest Drive, Suite 300 Houston, Texas 77042 832-781-8521 (Name, Address and |
|
| August 20, 2019 |
Exhibit 3.1 State Seal BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class or Series (PURSUANT TO NRS 78.1955) Filed in the office of /s/ Barbara K. Cegavske Barbara K. Cegavske Secretary of State State of Nevada Document Number 20170214105-63 Filing Date |
|
| August 16, 2019 |
Certificate of Correction to Amendment to Certificate of Designation filed February 14, 2018 Exhibit 3.2 State Seal BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate of Correction (PURSUANT TO NRS CHAPTERS 78, 78A, 80, 8l, 82, 84, 86, 87, 87A, 88, 88A, 89 AND 92A) Filed in the office of /s/ Barbara K. Cegavske Barbara K. Cegavske Secretary of State State of Nevada Document Number 20180071268-05 F |
|
| August 16, 2019 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 2) (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2018 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 |
|
| August 16, 2019 |
Amendment to Certificate of Designation Series E Preferred Stock filed May 16, 2017 Exhibit 3.1 State Seal BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class or Series (PURSUANT TO NRS 78.1955) Filed in the office of /s/ Barbara K. Cegavske Barbara K. Cegavske Secretary of State State of Nevada Document Number 20170214105-63 Filing Date |
|
| August 2, 2019 |
SOAN / AngioSoma, Inc. 10-Q - Quarterly Report - FORM 10-Q 10-Q 1 angiosoma2019063010q.htm FORM 10-Q UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| May 15, 2019 |
SOAN / AngioSoma, Inc. 10-Q Quarterly Report FORM 10-Q UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma Inc. ( |
|
| April 26, 2019 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2018 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 |
|
| March 8, 2019 |
SOAN / AngioSoma, Inc. / Atwood Brent Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 1) Under the Securities Exchange Act of 1934 ANGIOSOMA INC. (Name of Issuer) Common Stock (Title of Class of Securities) 03476L102 (CUSIP Number) Brent Atwood 5000 Riverside Drive Ste 100E Bldg 6 Irving, Texas 75039 Telephone: (907) 738-8458 With a copy to: John Cooley 5000 Riverside Drive Ste 100 |
|
| March 8, 2019 |
EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing, along with all other such undersigned, on behalf of the Reporting Persons (as defined in the joint filing), of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value |
|
| March 8, 2019 |
EXHIBIT 99.2 Trading Data Name of Purchaser Purchase Date No. of Shares Purchased Price Per Share(1) Nature of Purchase(2) John Cooley 2/22/2019 25,000 0.02 Broker’s Transaction EQuine Holdings Charter Private Equity Fund XIII 13 1/8/2019 250,000 0.02 Broker’s Transaction Equine Charter Private Equity Fund XX 1/8/2019 196,417 0.02 Broker’s Transaction Equine Charter Private Equity Fund XX 2/15/201 |
|
| February 19, 2019 |
SOAN / AngioSoma, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma Inc |
|
| February 15, 2019 |
SOAN / AngioSoma, Inc. FORM NT 10-Q NT 10-Q 1 angiosoma20190214nt10q.htm FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tr |
|
| January 3, 2019 |
Subsidiaries of the Registrant (4) Exhibit 21 SUBSIDIARIES OF THE REGISTRANT SomaCeuticals, Inc. (a Texas corporation) AngioSoma Research, Inc. (a Texas corporation) First Titan Energy, LLC, (a Nevada limited liability company) First Titan Technical, LLC, (a Nevada limited liability company) |
|
| January 3, 2019 |
SOAN / AngioSoma, Inc. FORM 10-K (Annual Report) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2018 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma, Inc. (Exa |
|
| December 31, 2018 |
SOAN / AngioSoma, Inc. FORM NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report |
|
| December 26, 2018 |
SOAN / AngioSoma, Inc. / Atwood Brent Activist Investment SC 13D 1 angiosoma-atwood13d122618.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 ANGIOSOMA INC. (Name of Issuer) Common Stock (Title of Class of Securities) 03476L102 (CUSIP Number) Brent Atwood 5000 Riverside Drive Ste 100E Bldg 6 Irving, Texas 75039 Telephone: (907) 738-8458 With a copy to: John Cooley 5000 Rive |
|
| December 26, 2018 |
EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing, along with all other such undersigned, on behalf of the Reporting Persons (as defined in the joint filing), of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value |
|
| December 26, 2018 |
EX-99.2 3 ex992.htm TRADING DATA EXHIBIT 99.2 Trading Data Name of Purchaser Purchase Date No. of Shares Purchased Price Per Share(1) Nature of Purchase(2) John Cooley 12/14/2018 185,000 $0.019 Broker’s Transaction EQuine Holdings Charter Private Equity Fund XIII 13 12/14/2018 600,000 $0.029 Broker’s Transaction EQuine Holdings Charter Private Equity Fund XIII 13 12/17/2018 100,000 $0.018 Broker’s |
|
| December 13, 2018 |
AngioSoma Announces Acquisition of Diabetes Relief Exhibit 99.2 AngioSoma Announces Acquisition of Diabetes Relief Houston, TX, December 13, 2018 – AngioSoma (OTC: SOAN) announced today the Company has entered into a partially binding letter of intent to acquire 100% of the equity interests in Diabetes Relief LLC. Diabetes Relief licenses medical facilities for the treatment of metabolic disorder, specializing in diabetes, for the use of patented |
|
| December 13, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 13, 2018 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 000-55072 27-3480481 (State or other jurisdiction of incorporation) (Commission File Num |
|
| December 13, 2018 |
2500 Wilcrest Drive, 3rd Floor Houston, Texas 77042 Exhibit 99.1 December 1, 2018 Diabetes Relief LLC 11511 Katy Freeway, Suite 100 Houston, Texas 77079 Attn: Hunter M.A. Carr, Manager Re: Proposal by AngioSoma, Inc., a Nevada publicly owned corporation, to acquire all the issued and outstanding membership interests in Diabetes Relief LLC, a Texas series limited liability company. Ladies and Gentlemen: The purpose of this letter (“Letter of Intent” |
|
| August 1, 2018 |
SOAN / AngioSoma, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma Inc. (E |
|
| June 19, 2018 |
AngioSoma, Inc. Announces Selection of Regulatory Firm for Flagship Drug EXHIBIT 99.1 http://www.soma-ceuticals.com AngioSoma, Inc. Announces Selection of Regulatory Firm for Flagship Drug HOUSTON, TX, June 18, 2018 (GLOBE NEWSWIRE) - AngioSoma, Inc. (SOAN) is excited to announce that we have identified a regulatory firm who can assist taking our patented flagship drug, LiprostinTM, through the FDA approval process. The regulatory firm will begin with a presubmission m |
|
| June 19, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 14, 2018 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 000-55072 27-3480481 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 21, 2018 |
SOAN / AngioSoma, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma Inc. ( |
|
| May 15, 2018 |
SOAN / AngioSoma, Inc. FORM 12B-25 (NT 10-Q) FOR 03-31-2018 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 October 31, 2018 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 000-55072 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10-D [] Form N-SAR [] Form N-CSR For Period Ended: March 31, 2018 |
|
| May 15, 2018 |
AngioSoma, Inc. (OTC: SOAN) Announces Grant of Patent for Flagship Drug EXHIBIT 99.1 http://www.soma-ceuticals.com AngioSoma, Inc. (OTC: SOAN) Announces Grant of Patent for Flagship Drug Houston, Texas May 14, 2018 (GLOBE NEWSWIRE) - AngioSoma, Inc. (SOAN) is excited to announce that the U.S. Patent Office has agreed to grant our patent application for our flagship pharmaceutical, LiprostinTM that is intended to treat Peripheral Artery Disease, or PAD. We are told the |
|
| May 15, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2018 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 000-55072 27-3480481 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 27, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 23, 2018 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 333-170315 27-3480481 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 15, 2018 |
SOAN / AngioSoma, Inc. FORM 12B-25 (NT 10-Q) FOR 12-31-2017 NT 10-Q 1 form12b-25.htm FORM 12B-25 (NT 10-Q) FOR 12-31-2017 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 October 31, 2018 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10 |
|
| February 15, 2018 |
SOAN / AngioSoma, Inc. FORM 10-Q QUARTERLY REPORT FOR 12-31-2017 (Quarterly Report) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2017 or [] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma |
|
| January 16, 2018 |
Subsidiaries of the Registrant Exhibit 21 SUBSIDIARIES OF THE REGISTRANT AngioSoma Research, Inc. (a Nevada corporation) AngioSoma Research, Inc. (a Texas corporation) First Titan Energy, LLC, (a Nevada corporation) First Titan Technical, LLC, (a Nevada corporation) |
|
| January 16, 2018 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2017 or [] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma, Inc. ( |
|
| January 10, 2018 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 30, 2017 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 333-170315 27-3480481 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 29, 2017 |
SOAN / AngioSoma, Inc. FORM 12B-25 (NT 10-K) FOR 09-30-2017 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 October 31, 2018 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [X] Form 10-K [] Form 20-F [] Form 11-K [] Form 10-Q [] Form 10-D [] Form N-SAR [] Form N-CSR For Period Ended: September 30, |
|
| December 18, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 18, 2017 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 333-170315 27-3480481 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 18, 2017 |
Exhibit 99.1 Angiosoma, Inc. (OTC: SOAN) Announces Agreement with Esther & Esther, Inc. to maximize sales of its OTC products with existing online marketing platform Conjunctionally, the company?s subsidiary, Soma Nutraceuticals Inc., completed a licensing agreement with Kentucky-based East Kentucky Organic, Inc. to begin manufacturing of Soma Nutraceutical?s product line, pending finalization of |
|
| September 18, 2017 |
Entry into a Material Definitive Agreement SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (D) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) September 12, 2017 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 333-170315 27-3480481 (State of Incorporation) (Commission File Number) (IRS Employer Identification |
|
| August 23, 2017 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A Amendment No. 1 (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or [] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-17 |
|
| August 18, 2017 |
AngioSoma FORM 10-Q QUARTERLY REPORT FOR 06-30-2017 (Quarterly Report) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or [] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma Inc. |
|
| August 14, 2017 |
AngioSoma FORM 12B-25 (NT 10-Q) FOR 06-30-2017 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 October 31, 2018 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10-D [] Form N-SAR [] Form N-CSR For Period Ended: June 30, 2017 |
|
| June 23, 2017 |
Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (D) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) June 21, 2017 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 333-170315 27-3480481 (State of Incorporation) (Commission File Number) (IRS Employer Iden |
|
| June 23, 2017 |
AUDIT COMMITTEE CHARTER EXHIBIT 14.1 AUDIT COMMITTEE CHARTER The Audit Committee (Committee) shall consist of a minimum of one director. As determined by the Board of Directors in accordance with applicable requirements, all members of the Committee shall be independent directors having no relationship that may interfere with the exercise of their objective judgment in discharging the responsibili |
|
| May 19, 2017 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) 10-Q 1 form10-q.htm FORM 10-Q QUARTERLY REPORT FOR 03-31-2017 UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or [] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition p |
|
| May 15, 2017 |
AngioSoma FORM 12B-25 (NT 10-Q) FOR 03-31-2017 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 October 31, 2018 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10-D [] Form N-SAR [] Form N-CSR For Period Ended: March 31, 201 |
|
| April 27, 2017 |
2016 Amended & Restated Omnibus Equity Incentive Plan Exhibit 4.6 FIRST TITAN CORP. 2016 AMENDED & RESTATED OMNIBUS EQUITY INCENTIVE PLAN 1. Purpose of this Plan This Plan has been adopted to promote the interests of the Corporation and its stockholders by strengthening the ability of the Company to attract, motivate and retain directors, employees and others in a position to affect the financial and operational performance of the Company. This plan |
|
| April 27, 2017 |
Form of exercisable Warrant to Purchase Common Stock of the Company Exhibit 4.5 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR REGISTERED OR QUALIFIED UNDER ANY STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS SUCH SALE, TRANSFER, PLEDGE OR HYPOTHECATION IS IN ACCORDANCE WITH SUCH ACT AND APPLICABLE STATE SECURITIES LAWS. Warrant No. No. of S |
|
| April 27, 2017 |
AngioSoma FORM S-8 REGISTRATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 27-3480481 (State or Other Jurisdiction of Incorporation or Organization) (IRS Employer Identification Number) 2500 Wilcrest Drive, 3rd Floor Houston, Texas 77042 (Address of Principal |
|
| April 27, 2017 |
Form of Certificate of Series B Preferred Stock Exhibit 4.3 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE TRANSFERRED OR SOLD UNLESS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN AVAILABLE EXEMPTION FROM REGISTRATION. Number Shares ANGIOSOMA, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF NEVADA This Certifies that is the owner of AND 00/100 F |
|
| April 27, 2017 |
Form of Certificate of Series A Preferred Stock Exhibit 4.2 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE TRANSFERRED OR SOLD UNLESS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN AVAILABLE EXEMPTION FROM REGISTRATION. Number Shares ANGIOSOMA, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF NEVADA This Certifies that is the owner of AND 00/100 F |
|
| April 27, 2017 |
Form of Certificate of Series E Preferred Stock Exhibit 4.4 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE TRANSFERRED OR SOLD UNLESS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN AVAILABLE EXEMPTION FROM REGISTRATION. Number Shares ANGIOSOMA, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF NEVADA This Certifies that is the owner of AND 00/100 F |
|
| April 10, 2017 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016 or [] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma |
|
| March 29, 2017 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2016 or [] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma, Inc. ( |
|
| March 29, 2017 |
Subsidiaries of the Registrant Exhibit 21 SUBSIDIARIES OF THE REGISTRANT AngioSoma Research, Inc. (a Nevada corporation) AngioSoma Research, Inc. (a Texas corporation) First Titan Energy, LLC, (a Nevada corporation) First Titan Technical, LLC, (a Nevada corporation) |
|
| March 1, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (D) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) June 28, 2016 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 333-170315 27-3480481 (State of Incorporation) (Commission File Number) (IRS Employer Identification Numb |
|
| February 22, 2017 |
Entry into a Material Definitive Agreement SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (D) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) February 21, 2017 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 333-170315 27-3480481 (State of Incorporation) (Commission File Number) (IRS Employer Identification |
|
| February 22, 2017 |
Exhibit 99.1 |
|
| February 15, 2017 |
AngioSoma FORM 12B-25 (NT 10-Q) FOR 12-31-2016 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 October 31, 2018 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10-D [] Form N-SAR [] Form N-CSR For Period Ended: December 31, |
|
| February 14, 2017 |
SOAN / AngioSoma, Inc. / SUMMERS DAVID P PHD - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Rule 13d-101 Under the Securities Exchange Act of 1934 AngioSoma, Inc. (Name of Issuer) Series E Preferred Stock, par value $.001 per share (Title of Class of Securities) None (CUSIP Number) Alex K. Blankenship 14001 Walden Road, Suite 600 Montgomery, Texas 77356 832-781-8521 (Name, Address and Telephone Number of |
|
| February 14, 2017 |
SOAN / AngioSoma, Inc. / Blankenship Alex K - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Rule 13d-101 Under the Securities Exchange Act of 1934 AngioSoma, Inc. (Name of Issuer) Series E Preferred Stock, par value $.001 per share (Title of Class of Securities) None (CUSIP Number) Alex K. Blankenship 14001 Walden Road, Suite 600 Montgomery, Texas 77356 832-781-8521 (Name, Address and Telephone Number of |
|
| February 14, 2017 |
Voting Agreement dated January 25, 2017, by and between Alex K. Blankenship and David P. Summers. Exhibit 99.1 |
|
| February 14, 2017 |
Voting Agreement dated January 25, 2017, by and between Alex K. Blankenship and David P. Summers. Exhibit 99.1 |
|
| December 30, 2016 |
AngioSoma FORM 12B-25 (NT 10-K) FOR 09-30-2016 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 October 31, 2018 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2016 o |
|
| November 14, 2016 |
Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (D) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) June 3, 2016 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 333-170315 27-3480481 (State of Incorporation) (Commission File Number) (IRS Employer |
|
| November 14, 2016 |
AngioSoma Research, Inc. Financial Statements May 31, 2016 Exhibit 99.1 AngioSoma Research, Inc. Financial Statements May 31, 2016 Contents Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Statement of Operations F-4 Statement of Changes in Stockholders? Equity (Deficit) F-5 Statement of Cash Flows F-6 Notes to the Financial Statements F-7 F-1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors An |
|
| October 5, 2016 |
EXHIBIT 99.2 |
|
| October 5, 2016 |
8-K 1 form8-k.htm FORM 8-K FOR 10-05-2016 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (D) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 5, 2016 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 333-170315 27-3480481 (State of Incorporation) (Commission Fi |
|
| October 5, 2016 |
AngioSoma, Inc. announces a Liprostin™ focused Joint Venture EXHIBIT 99.1 AngioSoma, Inc. announces a Liprostin? focused Joint Venture Montgomery, Texas (October 5th, 2016) AngioSoma, Inc. (OTCQB: SOAN) announces a joint venture with La Jolla Capital Partners LLC (?La Jolla?) focused on the funding and management of U S Food and Drug Administration (?FDA?) Liprostin? Phase III trials, as well as the licensing of Liprostin? worldwide thereafter. Liprostin? i |
|
| September 16, 2016 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A Amendment No. 1 (MARK ONE) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-17031 |
|
| September 13, 2016 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 AngioSoma Inc. (E |
|
| August 16, 2016 |
AngioSoma FORM 12B-25 (NT 10-Q) FOR 06-30-2016 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 October 31, 2018 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2016 o Trans |
|
| August 16, 2016 |
AngioSoma FORM 12B-25 (NT 10-Q) FOR 06-30-2016 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 October 31, 2018 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2016 o Trans |
|
| June 28, 2016 |
SOAN / AngioSoma, Inc. / SUMMERS DAVID P PHD - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 AngioSoma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03476L102 (CUSIP Number) June 22, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13 |
|
| June 27, 2016 |
SOAN / AngioSoma, Inc. / Kenwood Capital Llc - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 AngioSoma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03476L102 (CUSIP Number) June 22, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13 |
|
| June 22, 2016 |
First Titan Corp. Acquired AngioSoma, Inc. Exhibit 99.1 First Titan Corp. Acquired AngioSoma, Inc. Houston, Texas (June 22, 2016) ? First Titan Corp. (OTCQB: FTTN) (the ?First Titan?) is proud to announce the acquisition of AngioSoma, Inc., (OTCQB: SOAN (the ?Company?). The acquisition of AngioSoma, Inc. provides diversification for First Titan outside of the depressed oil & gas industry under the new name AngioSoma, Inc. and significant u |
|
| June 22, 2016 |
Exhibit 4.1 |
|
| June 22, 2016 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (D) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) June 17, 2016 AngioSoma, Inc. (Exact name of registrant as specified in its charter) Nevada 333-170315 27-3480481 (State of Incorporation) (Commission File Number) (IRS Employer Identification Numb |
|
| June 16, 2016 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A Amendment No. 1 (MARK ONE) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-55072 |
|
| June 7, 2016 |
First Titan Corp. Acquiring AngioSoma, Inc. Exhibit 99.1 First Titan Corp. Acquiring AngioSoma, Inc. Houston, Texas (June 7, 2016) ? First Titan Corp. (OTCQB: FTTN) (the ?Company?) is proud to announce the acquisition of AngioSoma, Inc., effective ten (10) days after the filing of a Form 14F with the SEC. The acquisition of AngioSoma, Inc. as a subsidiary of the Company provides diversification outside of the depressed oil & gas industry an |
|
| June 7, 2016 |
EXHIBIT 2.1 AGREEMENT AND PLAN OF REORGANIZATION AGREEMENT AND PLAN OF REORGANIZATION among FIRST TITAN CORP. (a Nevada corporation) ANGIOSOMA RESEARCH, INC. (a Texas corporation) ANGIOSOMA, INC. a Nevada corporation and THE STOCKHOLDERS OF ANGIOSOMA, INC. DATED AS OF June 3, 2016 TABLE OF CONTENTS RECITALS 1 ARTICLE 1 DEFINITIONS 1 ARTICLE 2. THE REORGANIZATION 6 Section 2.01. Basic Merger Transa |
|
| June 7, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2016 FIRST TITAN CORP. (Exact name of registrant as specified in its charter) Nevada 333-170315 27-3480481 (state or other jurisdiction of incorporation) (Commission File Numb |
|
| June 6, 2016 |
First Titan INFORMATION STATEMENT PURSUANT RULE 14F-1 INFORMATION STATEMENT PURSUANT TO REGULATION 14(F) OF THE SECURITIES EXCHANGE ACT OF 1934 AND SEC RULE 14f-1 THEREUNDER NOTICE OF CHANGE IN THE MAJORITY OF THE BOARD OF DIRECTORS June 6, 2016 We are furnishing this Information Statement to all of our shareholders of record at the close of business on June 3, 2016 of our common stock, $0. |
|
| May 23, 2016 |
SUBSIDIARIES OF THE REGISTRANT Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Company Type Jurisdiction First Titan Energy, LLC Limited Liability Company Nevada First Titan Technical, LLC Limited Liability Company Nevada |
|
| May 23, 2016 |
First Titan FORM 10-Q QUARTERLY REPORT FOR 03-31-2016 (Quarterly Report) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-55072 FIRST TITAN CORP. ( |
|
| May 17, 2016 |
First Titan FORM 12B-25 (NT 10-Q) FOR 03-31-2016 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 October 31, 2018 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2016 o Tran |
|
| February 22, 2016 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2015 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-55072 FIRST TITAN CORP |
|
| February 22, 2016 |
SUBSIDIARIES OF THE REGISTRANT Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Company Type Jurisdiction First Titan Energy, LLC Limited Liability Company Nevada First Titan Technical, LLC Limited Liability Company Nevada |
|
| February 17, 2016 |
AngioSoma FORM 12B-25 (NT 10-Q) FOR 12-31-2015 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 August 31, 2015 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2015 o Tr |
|
| January 22, 2016 |
Exhibit 3.2 FIRST TITAN CORP. A Nevada Corporation BYLAWS ARTICLE I Principal Executive Office The principal office of the Corporation shall be located at 495 Grand Boulevard, Suite 206, Miramar Beach, Florida 32550. The Board of Directors shall have the power and discretion to change from time to time the location of the principal office of the Corporation. ARTICLE II Stockholders Section 1. Plac |
|
| January 22, 2016 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K /A Amendment No. 1 (MARK ONE) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2015 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-55072 FIRS |
|
| January 13, 2016 |
SUBSIDIARIES OF THE REGISTRANT Exhibit 21 SUBSIDIARIES OF THE REGISTRANT First Titan Energy, LLC, a Nevada corporation, is a wholly owned subsidiary of First Titan Corp. First Titan Technical, LLC, a Nevada corporation, is a wholly owned subsidiary of First Titan Corp. Company Type Jurisdiction First Titan Energy, LLC Limited Liability Company Nevada First Titan Technical, LLC Limited Liability Company Nevada |
|
| January 13, 2016 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2015 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-55072 FIRST TITAN CORP. (Exac |
|
| December 30, 2015 |
AngioSoma FORM 12B-25 (NT 10-K) FOR 09-30-2015 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 October 31, 2018 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 0-55072 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2015 o Tra |
|
| September 24, 2015 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A Amendment No. 1 (MARK ONE) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-17031 |
|
| September 17, 2015 |
Exhibit 21 SUBSIDIARIES OF THE REGISTRANT First Titan Energy, LLC, a Nevada corporation, is a wholly owned subsidiary of First Titan Corp. First Titan Technical, LLC, a Nevada corporation, is a wholly owned subsidiary of First Titan Corp. |
|
| September 17, 2015 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A Amendment No. 1 (MARK ONE) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-1703 |
|
| August 17, 2015 |
AngioSoma FORM 12B-25 (NT 10-Q) FOR 06-30-2015 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 August 31, 2015 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2015 o Transi |
|
| August 17, 2015 |
SUBSIDIARIES OF THE REGISTRANT Exhibit 21 SUBSIDIARIES OF THE REGISTRANT First Titan Energy, LLC, a Nevada corporation, is a wholly owned subsidiary of First Titan Corp. First Titan Technical, LLC, a Nevada corporation, is a wholly owned subsidiary of First Titan Corp. |
|
| August 17, 2015 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 FIRST TITAN CORP. |
|
| May 15, 2015 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 FIRST TITAN CORP |
|
| May 15, 2015 |
SUBSIDIARIES OF THE REGISTRANT Exhibit 21 SUBSIDIARIES OF THE REGISTRANT First Titan Energy, LLC, a Nevada corporation, is a wholly owned subsidiary of First Titan Corp. First Titan Technical, LLC, a Nevada corporation, is a wholly owned subsidiary of First Titan Corp. |
|
| May 12, 2015 |
AngioSoma FORM 8-K FOR 05-08-2015 (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2015 FIRST TITAN CORP. (Exact name of registrant as specified in its charter) Florida 333-170315 27-3480481 (state or other jurisdiction of incorporation) (Commission File Numb |
|
| April 8, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| March 31, 2015 |
AngioSoma PRELIMINARY PROXY STATEMENT AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Amendment No. 3 INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confiden |
|
| March 24, 2015 | ||
| March 24, 2015 |
AngioSoma PRELIMINARY PROXY STATEMENT AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Amendment No. 2 INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confiden |
|
| February 27, 2015 |
SOAN / AngioSoma, Inc. PRER14A - - PRELIMINARY PROXY STATEMENT AMENDMENT NO. 1 PRER14A 1 pre14a.htm PRELIMINARY PROXY STATEMENT AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Amendment No. 1 INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Ch |
|
| February 27, 2015 |
SOAN / AngioSoma, Inc. CORRESP - - S O N F I E L D & S O N F I E L D A Professional Corporation LEON SONFIELD (1865-1934) GEORGE M. |
|
| February 17, 2015 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2014 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 FIRST TITAN C |
|
| February 17, 2015 |
SUBSIDIARIES OF THE REGISTRANT Exhibit 21 SUBSIDIARIES OF THE REGISTRANT First Titan Energy, LLC, a Nevada corporation, is a wholly owned subsidiary of First Titan Corp. First Titan Technical, LLC, a Nevada corporation, is a wholly owned subsidiary of First Titan Corp. |
|
| January 27, 2015 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K /A Amendment No. 1 (MARK ONE) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2014 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 F |
|
| January 27, 2015 |
SUBSIDIARIES OF THE REGISTRANT Exhibit 21 SUBSIDIARIES OF THE REGISTRANT First Titan Energy, LLC, a Nevada corporation, is a wholly-owned subsidiary of First Titan Corp. First Titan Technical, LLC, a Nevada corporation, is a wholly-owned subsidiary of First Titan Corp. |
|
| January 22, 2015 |
SOAN / AngioSoma, Inc. PRE 14A - - PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of |
|
| January 14, 2015 |
SUBSIDIARIES OF THE REGISTRANT Exhibit 21 SUBSIDIARIES OF THE REGISTRANT First Titan Energy, LLC, a Nevada corporation, is a wholly-owned subsidiary of First Titan Corp. First Titan Technical, LLC, a Nevada corporation, is a wholly-owned subsidiary of First Titan Corp. |
|
| January 14, 2015 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2014 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 FIRST TITAN CORP. (E |
|
| December 30, 2014 |
SOAN / AngioSoma, Inc. NT 10-K - - FORM 12B-25 (NT 10-K) 09-30-2014 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 August 31, 2015 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2014 o T |
|
| November 20, 2014 |
8-K 1 form8-k.htm FORM 8-K FOR 11-14-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 14, 2014 Commission File Number 333-170315 First Titan Corp. (Exact name of small business issuer as specified in its charter) Florid |
|
| September 29, 2014 |
8-K 1 form8-k.htm FORM 8-K FOR 09-23-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 23, 2014 Commission File Number 333-170315 First Titan Corp. (Exact name of small business issuer as specified in its charter) Flori |
|
| September 4, 2014 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A Amendment No. 1 (MARK ONE) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-17031 |
|
| August 19, 2014 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 FIRST TITAN CORP. |
|
| August 19, 2014 |
SUBSIDIARIES OF THE REGISTRANT Exhibit 21 SUBSIDIARIES OF THE REGISTRANT First Titan Energy, LLC, a Nevada corporation, is a wholly-owned subsidiary of First Titan Corp. First Titan Technical, LLC, a Nevada corporation, is a wholly-owned subsidiary of First Titan Corp. |
|
| August 15, 2014 |
SOAN / AngioSoma, Inc. NT 10-Q - - FORM 12B-25 (NT 10-Q) FOR 06-30-2014 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 August 31, 2015 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2014 o Transi |
|
| May 20, 2014 |
UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-170315 FIRST TITAN CORP |
|
| May 16, 2014 |
- FORM 12B-25 (NT 10-Q) FOR 03-31-2014 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 August 31, 2015 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2014 o Trans |
|
| April 9, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 14, 2014 Commission File Number 333-170315 First Titan Corp. (Exact name of small business issuer as specified in its charter) Florida 27-3480481 (State or other jurisdiction of |
|
| April 9, 2014 |
OIL & GAS PARTICIPATION AND OPERATING AGREEMENT MUSTANG PROJECT – BELL, MILAM, FALLS, ROBERTSON, LIMESTONE, FREESTONE, LEON, MADISON, BRAZOS COUNTIES, TEXAS This Oil & Gas Development and Operating Agreement (this “Agreement”) is made and entered into effective as of the date defined herein as the “Effective Date,” by and between SOHO RESOURCE HOLDINGS I, LLC (the “Company”) and the undersigned individual or entity (“Participant”) (collectively, the “Parties”). |
|
| April 9, 2014 |
8-K/A 1 form8-k.htm FORM 8-K/A AMENDMENT NO. 1 FOR 03-17-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K /A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 17, 2014 Commission File Number 333-170315 First Titan Corp. (Exact name of small business issuer |
|
| March 21, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 17, 2014 Commission File Number 333-170315 First Titan Corp. (Exact name of small business issuer as specified in its charter) Florida 27-3480481 (State or other jurisdiction of |
|
| February 21, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A Amendment No. 1 (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2013 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: |
|
| February 14, 2014 |
AngioSoma FORM 10-Q QUARTERLY REPORT FOR 12-31-2013 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2013 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 333-170315 FIRST T |
|
| January 23, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K /A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K /A Amendment No. 1 x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from , 20, to , 20 Commission File Number: 333-170315 Fir |
|
| January 14, 2014 |
AngioSoma FORM 10-K ANNUAL REPORT FOR 09-30-2013 (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _, 20_, to _, 20_ Commission File Number: 333-170315 First Titan Corp. |
|
| December 31, 2013 |
- FORM 12B-25 (NT 10-K) 09-30-2013 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 August 31, 2015 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2013 o T |
|
| October 8, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 3, 2013 Commission File Number 333-170315 First Titan Corp. (Exact name of small business issuer as specified in its charter) Florida 27-3480481 (State or other jurisdiction of |
|
| September 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 FIRST TITAN CORP. (Exact name of registrant as specified in its charter) Florida 27-3480481 (State or other jurisdiction of (I.R.S. Employer Incorporation or organization) Identification Number) 49 |
|
| August 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2013 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 333-170315 FIRST TITAN |
|
| May 16, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A Amendment No. 1 (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2013 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 33 |
|
| May 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2013 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 333-170315 FIRST TITA |
|
| March 7, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K/A Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K/A Amendment No. 2 x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended September 30, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from , 20, to , 20 Commission File Number: 333-170315 Fi |
|
| March 7, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A Amendment No. 1 (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2012 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: |
|
| February 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2012 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 333-170315 FIRST T |
|
| February 7, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 1, 2013 Commission File Number 333-170315 First Titan Corp. (Exact name of small business issuer as specified in its charter) Florida 27-3480481 (State or other jurisdiction o |
|
| February 7, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K/A Amendment No. 1 x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended September 30, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from , 20, to , 20 Commission File Number: 333-170315 Fi |
|
| January 15, 2013 |
8-K 1 form8-k.htm FORM 8-K FOR 12-27-2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2012 FIRST TITAN CORP. (Exact name of registrant as specified in its charter) FL 333-170315 27-3480481 (state or other jurisdict |
|
| January 15, 2013 |
Exhibit 16.1 Peter Messineo Certified Public Accountant 1982 Otter Way Palm Harbor FL 34685 [email protected] T 727.421.6268 F 727.674.0511 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 December 27, 2012 Dear Sir/Madam: We have read the statements included in the Form 8-K dated December 27, 2012, of First Titan Corp., to be filed with the |
|
| January 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended September 30, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from , 20, to , 20 Commission File Number: 333-170315 First Titan Corp. (E |
|
| January 2, 2013 |
- FORM 12B-25 (NT 10-K) 09-30-2012 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 August 31, 2015 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2012 o T |
|
| December 7, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2011 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: |
|
| December 7, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2012 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 333 |
|
| December 7, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 2 (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2012 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 333- |
|
| October 22, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K/A Amendment No. 1 x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended September 30, 2011 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from , 20, to , 20 Commission File Number 333-170315 Fir |
|
| October 19, 2012 |
October 19, 2012 Via EDGAR Brian Cascio Accounting Branch Chief Division of Corporation Finance Securities and Exchange Commission Washington, D. |
|
| September 20, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2012 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 333- |
|
| August 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2012 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 333-170315 FIRST TITAN |
|
| May 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2012 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 333-170315 FIRST TITA |
|
| May 15, 2012 |
- FORM 12B-25 (NT 10-Q) 03-31-2012 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: 3235-0058 May 31, 2012 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 333-170315 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2012 o Transiti |
|
| March 16, 2012 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 First Titan Corporation (Exact name of registrant as specified in its charter) Florida 27-3480481 (State or Other Jurisdiction of Incorporation or Organization) (IRS Employer Identification Number) 6846 Tailfeather Way Bradenton, FL 34204 (Address of Principal Executive Office |
|
| March 16, 2012 |
First Titan Corp. 2012 Stock Plan for Directors, Officers and Consultants Exhibit 4.1 First Titan Corp. 2012 Stock Plan for Directors, Officers and Consultants SECTION 1. PURPOSE OF THE PLAN. The purpose of the 2012 Stock Plan for Directors, Officers and Consultants (“Plan”) is to enhance the ability of First Titan Corp., a Florida corporation (the “Company”), to attract and retain highly qualified and experienced directors, employees and consultants and to give such di |
|
| February 14, 2012 |
Working Interest Purchase and Sale Exhibit 10.1 Working Interest Purchase and Sale THIS WORKING INTEREST PURCHASE AND SALE AGREEMENT (?the Agreement?) is made and entered into effective the 19th day of January, 2012, by and between MESA CHICA GEOPHYSICAL, INC. whose address is P. 0. Box 781046, San Antonio, TX 78278, represented herein by its duly authorized President, Trace Maurin and FIRST TITAN CORP whose address is 495 Grand Bo |
|
| February 14, 2012 |
10-Q 1 form10-q.htm FORM 10-Q QUARTERLY REPORT FOR 12-31-2011 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2011 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSI |
